124 related articles for article (PubMed ID: 36622694)
1. Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406).
Cranmer LD; Lu Y; Heise RS; Ballman KV; Loggers ET; Pollack SM; Wagner MJ; Reinke DK; Schöffski P; Tap WD
Clin Cancer Res; 2023 Mar; 29(6):1068-1076. PubMed ID: 36622694
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.
Tap WD; Papai Z; Van Tine BA; Attia S; Ganjoo KN; Jones RL; Schuetze S; Reed D; Chawla SP; Riedel RF; Krarup-Hansen A; Toulmonde M; Ray-Coquard I; Hohenberger P; Grignani G; Cranmer LD; Okuno S; Agulnik M; Read W; Ryan CW; Alcindor T; Del Muro XFG; Budd GT; Tawbi H; Pearce T; Kroll S; Reinke DK; Schöffski P
Lancet Oncol; 2017 Aug; 18(8):1089-1103. PubMed ID: 28651927
[TBL] [Abstract][Full Text] [Related]
3. Cardiac events among patients with sarcoma treated with doxorubicin by method of infusion: A real-world database study.
Cranmer LD; Hess LM; Sugihara T; Muntz HG
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1681. PubMed ID: 35852051
[TBL] [Abstract][Full Text] [Related]
4. The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma.
Constantinidou A; van der Graaf WTA
Eur J Cancer; 2017 Oct; 84():257-261. PubMed ID: 28841543
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors.
Casper ES; Gaynor JJ; Hajdu SI; Magill GB; Tan C; Friedrich C; Brennan MF
Cancer; 1991 Sep; 68(6):1221-9. PubMed ID: 1873773
[TBL] [Abstract][Full Text] [Related]
7. AI-Radiomics Can Improve Inclusion Criteria and Clinical Trial Performance.
Tomaszewski MR; Fan S; Garcia A; Qi J; Kim Y; Gatenby RA; Schabath MB; Tap WD; Reinke DK; Makanji RJ; Reed DR; Gillies RJ
Tomography; 2022 Feb; 8(1):341-355. PubMed ID: 35202193
[No Abstract] [Full Text] [Related]
8. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD
Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
11. Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial.
Jones RL; Wagner AJ; Kawai A; Tamura K; Shahir A; Van Tine BA; Martín-Broto J; Peterson PM; Wright J; Tap WD
Clin Cancer Res; 2021 Jul; 27(14):3861-3866. PubMed ID: 33632930
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas.
Hammer KJ; Copeland VC; Loggers ET; Pollack SM; Wagner MJ; Cranmer LD
Am J Clin Oncol; 2020 Jun; 43(6):446-451. PubMed ID: 32235164
[TBL] [Abstract][Full Text] [Related]
13. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.
Zalupski M; Metch B; Balcerzak S; Fletcher WS; Chapman R; Bonnet JD; Weiss GR; Ryan J; Benjamin RS; Baker LH
J Natl Cancer Inst; 1991 Jul; 83(13):926-32. PubMed ID: 2067035
[TBL] [Abstract][Full Text] [Related]
14. Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial.
Younger E; Ballman K; Lu Y; Pápai Z; Van Tine BA; Attia S; Schöffski P; Reinke D; Tap WD; Jones RL
J Geriatr Oncol; 2020 Apr; 11(3):463-469. PubMed ID: 31126845
[TBL] [Abstract][Full Text] [Related]
15. A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome.
Hamacher R; Liu X; Schuler MK; Hentschel L; Schöffski P; Kopp HG; Bauer S; Kasper B; Lindner L; Chemnitz JM; Crysandt M; Stein A; Steffen B; Richter S; Egerer G; Ivanyi P; Kunitz A; Grünwald V
Eur J Cancer; 2023 Mar; 181():145-154. PubMed ID: 36657323
[TBL] [Abstract][Full Text] [Related]
16. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
Karch A; Koch A; Grünwald V
Trials; 2016 Jul; 17(1):312. PubMed ID: 27387325
[TBL] [Abstract][Full Text] [Related]
18. A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcoma.
Van Tine BA; Agulnik M; Olson RD; Walsh GM; Klausner A; Frank NE; Talley TT; Milhem MM
Cancer Med; 2019 Jun; 8(6):2994-3003. PubMed ID: 31016866
[TBL] [Abstract][Full Text] [Related]
19. Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma.
Van Tine BA; Hirbe AC; Oppelt P; Frith AE; Rathore R; Mitchell JD; Wan F; Berry S; Landeau M; Heberton GA; Gorcsan J; Huntjens PR; Soyama Y; Vader JM; Alvarez-Cardona JA; Zhang KW; Lenihan DJ; Krone RJ
Clin Cancer Res; 2021 Jul; 27(14):3854-3860. PubMed ID: 33766818
[TBL] [Abstract][Full Text] [Related]
20. Novel-fosfamide monotherapy or in combination with doxorubicin versus doxorubicin alone in patients with advanced soft tissue sarcoma: A pooled analysis of randomized clinical trials.
Liu XX; Han YH; Kuang BH; Lin GH; Wang BC
Medicine (Baltimore); 2023 Aug; 102(33):e34902. PubMed ID: 37603507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
